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Abstract The composition of the human erythrocyte mem-
brane (RBC) glycoprotein- and glycolipid-bound sialic acids of
A, B, AB and O type donors was studied using a new method
(Zanetta et al., Glycobiology 11 (2001) 663^676). In addition to
Neu5Ac as the major compound, Kdn, Neu5,9Ac2, Neu5,7Ac2,
Neu (de-N-acetylated-Neu5Ac), Neu5Ac8Me, Neu5Ac9Lt,
Neu4,5Ac2, Neu5,8Ac29Lt and Neu5Ac8S were characterised.
Among these di¡erent compounds, Neu5Ac8Me, Neu5Ac9Lt,
Neu4,5Ac2, Neu5,8Ac29Lt and Neu5Ac8S have never been de-
scribed and quantitatively determined before in human tissues or
cells. Neu5Gc and its O-alkylated or O-acylated derivatives
were not detected.
8 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The sialic acid family presents a very large heterogeneity.
Besides the three di¡erent classes de¢ned by the diversity of
the substituents of the C(5) carbon atom (N-acetyl-neuraminic
acid, N-glycolyl-neuraminic acid and 3-deoxy-D-glycero-D-ga-
lacto-nonulosonic acid (Kdn)), some of the hydroxyl groups
can be substituted by acyl groups (O-acetyl, O-lactyl, O-sul-
phate, O-phosphate) or by methyl groups [1^3]. This hetero-
geneity is representative of a second degree of complexity of
glycoconjugates. The presence of O-methyl groups on glyco-
conjugate monosaccharides was previously observed in several
organisms such as 6-O-methyl-galactose [4] or 2-O-methyl-fu-
cose [5], due to the resistance of these substituents to the
classical techniques used for the cleavage of the glycosidic
bonds. In contrast, the O-acyl groups of most constitutive
monosaccharides are liberated under the conditions of glyco-
sidic bond cleavage. This contrasts with sialic acids since their
glycosidic bonds are generally labile in acidic conditions. This
o¡ered the possibility to examine the nature of these substitu-
ents in di¡erent tissues. Such determinations were generally
di⁄cult because of the necessity to perform the analysis start-
ing from large amounts of material (for review see [1]). How-
ever, a recent method developed in our laboratory [6] over-
came these problems of sensitivity since it did not require an
initial puri¢cation of sialic acids after acid hydrolysis before
analysis. Because of the stability of the volatile hepta£uoro-
butyrate (HFB) derivatives of the O-methyl esters used for the
gas chromatography (GC) mass spectrometry (MS) analysis,
on the one hand, and the very speci¢c fragmentation spectra
obtained by electron impact mass spectrometry, on the other
hand, it became possible to analyse sialic acids down to the
picogram level.
Since the sialic acid composition of human red blood cell
(RBC) membrane has not yet been reported in detail, we
analysed separately the glycoprotein- and glycolipid-bound
sialic acids of blood samples from individuals with A, B,
AB and O blood groups. The results reveal a very large diver-
sity of the glycoconjugate-bound sialic acids since in addition
to Neu5Ac as the major constituent, the following compounds
were identi¢ed: Neu5Ac8Me, Neu, Neu4,5Ac2, Neu5,7Ac2,
Neu5,9Ac2, Neu5Ac9Lt, Neu5,8Ac29Lt and Neu5Ac8S, as
well as traces of Kdn, but the total absence of Neu5Gc.
2. Materials and methods
2.1. Chemicals
Standard Neu5Ac and Neu5Gc were purchased from Sigma (St.
Louis, MO, USA). Neu4,5Ac2, Neu5,9Ac2 and Neu5,7,9Ac3 were a
generous gift from Prof. R. Schauer. Diazogen1 was from Aldrich
(Milwaukee, WI, USA) and hepta£uorobutyric anhydride (HFBAA;
puriss. grade) from Fluka (Buchs, Switzerland). Heavy walled screw
cap tubes (10U100 mm) and Te£on-lined caps (GL14) were from
Schott (Mainz, Germany).
2.2. Isolation of human RBC membranes and delipidation procedure
For the preparation of RBC membranes, human blood was taken
up on heparin from healthy individuals and washed thrice by centri-
fugation (for 5 min, 1000Ug at 4‡C) with phosphate-bu¡ered saline
(PBS: 25 mM sodium phosphate bu¡er pH 7.2 containing 150 mM
sodium chloride) in order to eliminate platelets and leukocytes by
pipetting the supernatant. RBC haemolysis was performed using
a 10-fold dilution of PBS in cold water (39 ml per ml RBC). After
vigorous agitation, the samples were centrifuged (20 min, 10000Ug at
4‡C) and the pellet was washed thrice in the lysis bu¡er and centri-
fuged in the same conditions. A last washing of the pellet was per-
formed in cold water in order to remove salts. Preparations were
considered suitable for analysis of sialic acids when the membrane
pellet was white.
For delipidation of the membranes, a ¢rst extraction was carried
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out for 30 min at room temperature under vigorous agitation with a
methanol/chloroform mixture (2:1, v/v) followed by centrifugation (15
min, 1200Ug). The supernatant was recovered and the pellet was
subjected to a second extraction carried out in the same conditions
with a methanol/chloroform mixture (1:2, v/v). Both supernatants
were pooled and evaporated under a stream of nitrogen. The dry
residue constituted the glycolipid fraction and the delipidated residue
the glycoprotein fraction.
2.3. Liberation and analysis of sialic acids
All operations were performed in heavy walled Te£on-lined screw
caps tubes. The glycoprotein- and the lipid-bound sialic acids were
analysed separately as previously described [6] with slight modi¢ca-
tions. For the liberation of sialic acids, all samples were hydrolysed
under the same conditions (105 min at 80‡C in 2 M acetic acid) and
cooled at 4‡C. Glycoprotein samples were centrifuged (1 h, 4000Ug at
4‡C) and the supernatant was transferred into new reaction vials and
lyophilised. For the glycolipid fraction, the samples were directly
lyophilised.
All the samples containing the free sialic acids were subjected to a
two-step derivatisation procedure: methyl esteri¢cation of the carbox-
yl group with diazomethane, followed by acylation of free alcohol and
amino groups with HFBAA. Taking into consideration that these
reagents are harmful to health, all operations have to be performed
under a well-ventilated hood. The dry samples were supplemented
with 200 Wl of anhydrous methanol and 200 Wl of a diazomethane
solution in diethyl ether [6] and left for at least 4 h at room temper-
ature after vigorous agitation. When the GC/MS analysis had to be
performed, the samples were treated individually as follows. Glyco-
protein samples were evaporated to dryness under a stream of nitro-
gen, then supplemented with 400 Wl acetonitrile and 50 Wl of HFBAA
and heated for 5 min at 150‡C in a sand bath. After cooling the
samples were evaporated under a stream of nitrogen, taken up in
400 Wl of acetonitrile dried on calcinated calcium chloride [6] and
an aliquot of 1 Wl was injected onto the Ross injector of the GC/
MS apparatus. Because of the very high amount of glycoprotein-
bound sialic acid in human RBC membranes, the optimal conditions
of analysis should be performed starting with less than 1 mg of RBC
membrane proteins. Otherwise, the quantities of reagents indicated
above have to be increased proportionally to obtain a complete deri-
vatisation and to avoid a saturation of the detector response for
Neu5Ac.
For glycolipids, the samples were treated with diazomethane and
HFBAA as above. Nevertheless, due to the low amount of sialic acids
in the lipid extracts and to the huge amount of cholesterol (obtained as
a volatile HFB derivative) overloading all GC/MS signals, a cleaning
procedure of the samples was applied. After acylation with HFBAA,
the samples were evaporated to dryness under a stream of nitrogen,
taken up in 1 ml of dried acetonitrile and the sample was supple-
mented with 1 ml of heptane (or hexane) and shaken. The upper
alkane phase containing the cholesterol derivative and fatty acid
methyl esters was discarded. This operation was repeated once. The
¢nal remaining lower phase was re-acylated with HFBAA as de-
scribed above, dried under a stream of nitrogen, taken up in dried
acetonitrile and injected onto the Ross injector of the GC/MS appa-
ratus.
2.4. Gas chromatography and mass spectrometry
The GC separation was performed on a Carlo Erba GC 8000 gas
chromatograph equipped with a 25 mU0.32 mm CP-Sil5 CB Low
bleed/MS capillary column, 0.25 Wm ¢lm phase (Chrompack France,
Les Ulis, France). The temperature of the Ross injector was 260‡C
and the samples were analysed using the following temperature pro-
gramme: 90‡C for 3 min and then 5‡C/min until 260‡C. The column
was coupled to a Finnigan Automass II mass spectrometer (mass
detection limit 1000) or, for masses larger than 1000, to a Riber 10-
10H mass spectrometer (mass detection limit 2000). The analyses were
performed routinely in the electron impact mode (ionisation energy 70
eV; source temperature 150‡C). In order to preserve the ¢lament of
the ionisation source, the GC/MS records were performed 5 min after
the injection of the sample. The quantitation of the sialic acids was
performed on the chromatogram reconstituted for the ion at m/z=169
speci¢c of HFB derivatives. This procedure eliminated all interference
due to di¡erent contaminants eluted in the area of the retention times
of the di¡erent sialic acid derivatives.
3. Results and discussion
Consistent with the data of the literature [7,8], our study
showed that the majority of sialic acids of human RBC mem-
branes was associated with glycoproteins, the lipid-bound
sialic acids always representing less than 4% of the total sialic
acids. Nevertheless, the lipid-bound sialic acids varied accord-
ing to the blood group: around 0.30% of the total sialic acid
acids for blood groups A and B and ¢ve-fold and 10-fold
higher in blood groups AB and O, respectively (Table 1). In
contrast to previous studies, the GC/MS analysis of RBC
sialic acid revealed a large diversity of these compounds, es-
pecially for glycoprotein-bound sialic acids.
In fact, besides the major sialic acid Neu5Ac, nine other
sialic acids were detected in the glycoprotein fraction (Table
Table 1
Distribution of glycoprotein- and glycolipid-bound sialic acids in human erythrocyte membranes of A+, B+, AB+, O+ blood type donors
Group A (%) Group O (%) Group B (%) Group AB (%)
Glycolipid
Neu5Ac 89.41 (85.3^95.8) 92.01 (88.5^97.6) 83.04 (72.3^100) 83.47 (69.6^93.4)
Neu5Ac8Me 0.00 0.00 3.4 (0^10.2) 0.00
Neu5Ac9Lt 0.00 0.00 2.29 (0^6.9) 0.00
Neu5,9Ac2 10.59 (4.17^14.7) 0.82 (0^1.7) 0.00 0.00
Neu 0.00 7.17 (1.7^9.8) 11.27 (0^23.2) 16.53 (6.6^30.4)
% of total sialic acid 0.33 (0.09^0.58) 3.67 (3.56^3.80) 0.29 (0.16^0.53) 1.54 (0.39^2.20)
Glycoprotein
Kdn 0.06 (0.04^0.07) 0.07 (0^0.19) 0.17 (0.11^0.27) 0.06 (0.00^0.13)
Neu5Ac 86.76 (83.39^90.27) 84.53 (79.77^87.66) 85.66 (83.19^87.74) 78.26 (76.43^80.08)
Neu5Ac8Me 1.6 (0.23^3.06) 2.36 (2.00^3.21) 2.55 (2.25^3.00) 1.67 (1.18^2.16)
Neu5Ac9Lt 1.2 (0.22^2.24) 4.12 (1.97^5.05) 2.86 (2.07^3.45) 8.14 (5.83^10.44)
Neu5,9Ac2 0.34 (0.23^0.50) 0.31 (0.21^1.23) 0.23 (0.17^0.29) 0.14 (0.13^0.15)
Neu4,5Ac2 0.53 (0.44^0.66) 0.50 (0.24^1.01) 0.19 (0.00^0.37) 0.33 (0.29^0.37)
Neu 3.88 (2.81^5.20) 4.44 (3.25^7.64) 3.72 (3.25^4.63) 5.21 (4.71^5.70)
Neu5,7Ac2 0.34 (0.16^0.60) 0.24 (0.13^0.36) 0.18 (0.13^0.23) 0.17 (0.16^0.17)
Neu4,5Ac29Lt 3.98 (1.45^5.34) 2.23 (0.51^4.64) 2.93 (2.46^3.70) 3.94 (2.10^5.79)
Neu5Ac8S 1.30 (1.13^1.58) 0.65 (0.52^0.79) 1.02 (0.45^1.16) 0.93 (0.85^1.01)
KdnAcx absent 0.54 (0.00^1.25) 0.49 (0.29^0.74) 1.16 (0.00^2.33)
Neu5Gc absent absent absent absent
% of total sialic acid 99.67 (99.91^99.42) 96.33 (96.44^96.20) 99.71 (99.84^99.47) 98.46 (99.61^97.80)
Data were obtained from three di¡erent donors in each blood group and are expressed as mean and experimental variation.
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1) in the order of their GC retention times: Kdn, Neu5-
Ac8Me, Neu5Ac9Lt, Neu5,9Ac2, Neu4,5Ac2, Neu, Neu5,7-
Ac2, Neu5,8Ac29Lt and Neu5Ac8S. In addition, a di-O-ace-
tylated Kdn was detected.
Kdn was unambiguously identi¢ed since this compound
showed a very typical GC elution pro¢le, since it was the ¢rst
compound of the sialic acid series to be eluted on classical
methyl-siloxane liquid phases [6], its anomers being eluted in
an area of the GC/MS chromatogram relatively free of con-
taminants so that a very low amount of this compound could
be unambiguously identi¢ed by its fragmentation pattern (Fig.
1B). This observation con¢rmed the ¢nding of Inoue et al. [9],
reporting the presence of Kdn in human RBC. In these mem-
branes, Kdn represented less than 0.2% of Neu5Ac and was
undetectable in one sample of the B group and one sample of
the AB group. The presence of a relatively more abundant
compound of the Kdn family was detected (relative retention
time to Neu5Ac= 1.138), showing fragmentation ions charac-
teristic of a di-O-acetylated Kdn derivative [6]. However, since
compounds with identical fragmentation patterns to those
identi¢ed in the previous study [6] were not found in our
analyses, the position of the O-acetyl groups could not be
determined.
Neu5Ac8Me, which was identi¢ed for the ¢rst time in mam-
malian tissues using our method [6], was characterised by its
retention time and its speci¢c ions at m/z=578 and 805 (Fig.
1C). Its presence in human RBC was veri¢ed in samples sub-
jected to acid-catalysed methanolysis, followed by GC/MS
analysis of HFB derivatives [10], since this compound behaves
di¡erently from the derivative of Neu5Ac due to the stability
of the 8-O-methyl group to methanolysis. This compound was
found at higher levels in the RBC of the AB group in which it
represented up to 10% in one individual.
A second not yet identi¢ed sialic acid in human was Neu5-
Ac9Lt, a compound characterised by an intense ion at m/z=
112, which is characteristic of 9-O-lactylated sialic acids [6]
and by a speci¢c fragmentation pattern (Fig. 1D). This com-
pound was particularly abundant in RBC of the O and AB
groups in which it represented more than 10% of the total
sialic acids in one of the samples (Table 1).
Neu5,9Ac2 was the only O-acetylated sialic acid already
described in human RBC [11^13], evidenced by speci¢c lectins
[14^18], but quantitative data on its amount in human RBC
had not been determined before. Using GC/MS analysis, this
compound was characterised by a series of speci¢c ions at
m/z=862, 490 and 73 (Fig. 1E). In all our analyses, this sialic
acid was a very minor compound, always representing less
than 1.5% of the total sialic acids.
Using our method, Neu4,5Ac2 was for the ¢rst time iden-
ti¢ed in human tissue or cells. In fact, it was detected at a
similar level as Neu5,9Ac2 in all human RBC samples so far
analysed, except in one of the B group, and was characterised
by its retention time and speci¢c ions at m/z=861 and 491
(Fig. 1F).
Neu (N-de-acetylated Neu5Ac) was also for the ¢rst time
reported to be present in all RBC samples. It was unambigu-
ously identi¢ed by its retention time and speci¢c ions at m/
z=505 and 815 (Fig. 1G). The presence of this compound was
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Fig. 1. Electron impact mass spectra of the HFB derivatives of the methyl esters of sialic acids: (A) Neu5Ac; (B) Kdn; (C) Neu5Ac8Me;
(D) Neu5Ac9Lt; (E) Neu5,9Ac2 ; (F) Neu4,5Ac2 ; (G) Neu; (H) Neu5,7Ac2 ; (I) Neu5,8Ac29Lt; (J) Neu5Ac8S (all the spectra shown here were
obtained on human RBC material). In C, D, E, G, H and I the bars with ‘U5’ correspond to a ¢ve-fold ampli¢cation of the signal. Reporter
ions important for the identi¢cation of the di¡erent compounds are underlined. Note in A and B that common ions to Neu5Ac and Kdn di¡er
from 1 atomic mass unit.
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not due to a methodological artefact [6], since it was always
found only in speci¢c samples and since its level in commer-
cially available Neu5Ac standard subjected to the entire pro-
cedure of hydrolysis and derivatisation was less than 0.01% of
Neu5Ac. Furthermore, the presence of this compound in hu-
man tissues was indirectly presumed using speci¢c antibodies
and by the loss of immunoreactivity upon N-acetylation [19].
In addition, it was demonstrated that this compound was
over-expressed in some malignant tumours [19^21], a point
also supported by our recent studies (Zanetta et al., in prep-
aration). Its higher relative abundance in the AB group gly-
colipid fraction was not observed in the glycoprotein fraction.
Neu5,7Ac2, which was characterised by its retention time
and its fragmentation pattern with ions at m/z=150, 494, 790
and 862 (Fig. 1H), has never been reported before in human
RBC. It was detected in all samples at a very low level.
A relatively abundant minor sialic acid, Neu5,8Ac29Lt, was
actually found in all RBC samples, but more abundant in
RBC of the AB group. This compound was easily identi¢ed
by its ion at m/z=112 and intermediate intensity ions at m/z=
195 and 255 (Fig. 1I). No other mono-O-acetylated-9-O-lacty-
lated compounds could be detected.
Neu5Ac8S was only recently identi¢ed in mammalian tis-
sues [6], but the present article demonstrated for the ¢rst time
its presence in humans, although it was present at a low level
in all RBC membranes. This compound was easily detected by
its retention time and its characteristic fragmentation pattern
including a series of speci¢c ions at m/z=122, 295 and 365
([6] ; Fig. 1J). It always represented more than 0.5% of the
total sialic acids.
Because of contradictory data in the literature, particular
attention is drawn to Neu5Gc as a constituent of RBC mem-
branes. Our study clearly excluded its presence in human
RBC. In our GC/MS system, Neu5Gc has a speci¢c retention
time and a speci¢c fragmentation pattern [6] and quantities of
this compound as low as 1039 relative to Neu5Ac could be
detected. Nevertheless, we never found any trace suggesting
the presence of this compound. Therefore, these data obtained
on RBC contradicted some previous reports [22] suggesting
the presence of Neu5Gc derivatives in these membranes.
Based on the examination of the precise biosynthetic path-
ways of sialic acids, it was proposed that human tissues could
not synthesise Neu5Gc [23,24]. This view was also supported
by the fact that multiple analyses of normal and cancerous
human tissues did not allow the detection of traces of
Neu5Gc. Previous data suggesting the presence of Neu5Gc
in some tumour-speci¢c antigens could be due to the presence
of another sialic acid derivative, the 1,7 intramolecular lactone
of Neu5Ac [6], a compound very stable in acidic or alkaline
media and likely at the origin of this confusion, as discussed
elsewhere [6]. This lactone was totally absent from the RBC
samples analysed in this study, but was present (sometimes at
very high level in some malignant tumours).
In the domain of lipid-bound sialic acids, besides Neu5Ac,
which is always the major compound, only Neu5Ac8Me,
Neu5Ac9Lt, Neu5,9Ac2 and Neu were detected at di¡erent
levels (Table 1). Neu5Ac8Me was only detected in RBC of
two individuals of the B group and absent from the other
samples, as was Neu5Ac9Lt. In contrast, Neu5,9Ac2 was
only present at a relatively high level in all the individuals
of the A group (and one of the O group at a much lower
level), whereas it was not detectable in the other samples. Neu
was never detected in the lipid-bound sialic acids in the A
group, but was found in all individuals of the AB group
and at a lower level in all individuals of the O group (Table
1). Because of the relative heterogeneity of the data, it was
di⁄cult to conclude to an association of speci¢c sialic acids
with blood groups, the heterogeneity likely representing an
individual speci¢city. Nevertheless, we could suggest that the
presence of lipid-bound Neu5,9Ac2 was more associated with
the A group, Neu with the AB group and Neu5Ac9Lt with
the B group.
4. Conclusions and perspectives
This GC/MS study shows for the ¢rst time a very high
heterogeneity of the sialic acids in human RBC membranes,
especially in the glycoprotein fraction, leading to the iden-
ti¢cation of 10 sialic acids. It con¢rms previous studies indi-
cating that besides the major sialic acid Neu5Ac, two other
sialic acids (Kdn and Neu5,9Ac2) are present in these mem-
branes and were unambiguously identi¢ed and quanti¢ed
using an appropriate physico-chemical technique [6]. The ex-
istence of de-N-acylated sialic acid (Neu), suggested by in-
direct methods, was also veri¢ed. Six other di¡erent sialic
acids, which had not been identi¢ed before in human tissues,
could be unambiguously demonstrated in human RBC mem-
branes, i.e. Neu5Ac8Me, Neu5Ac9Lt, Neu4,5Ac2, Neu5,7Ac2,
Neu5,8Ac29Lt and Neu5Ac8S at signi¢cant levels, but the
presence of Neu5Gc is excluded. This study also shows that
the population of glycoprotein-linked sialic acids in human
RBC membranes is more complex than that of the glycoli-
pid-bound sialic acids. Despite the importance of the varia-
tions in the sialic acids of RBC membranes of the di¡erent
individuals of the same blood group, this study shows a quite
speci¢c association of Neu5,9Ac2 with glycolipids of the A
group, of Neu with glycolipids of the AB group and of Neu5-
Ac9Lt with glycoproteins of the AB group, the reason for
these associations remaining obscure. The presence of these
new compounds gives rise to fundamental questions on the
biological signi¢cance of the diversity of the sialic acid in
human tissues, their biosynthetic and degradation pathways
and their involvement in the normal and pathological physi-
ology of humans.
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